单用吉西他滨治疗老年晚期非小细胞肺癌的有效性及安全性探讨

The efficacy and safety of gemcitabine alone for elderly patients with advanced non-small cell lung cancer

目的探讨吉西他滨治疗老年晚期非小细胞肺癌的临床价值。方法选择2008年1月～2010年1月本院收治的晚期非小细胞肺癌老年患者80例，分为观察组和对照组各40例，针对患者内科疾病进行调理，观察组抗肿瘤药物单纯应用吉西他滨，对照组应用顺铂联合紫杉醇。比较两组患者的不良反应，统计其2年局部区域控制率、无新发远处转移率及总生存率。结果观察组发生白细胞减少、血小板减少及胃肠道反应Ⅰ、Ⅱ、Ⅲ级的比率均低于对照组（P〈O．05）．2年局部区域控制率、无新发远处转移率及总生存率均显著高于对照组（P〈O．05），疾病进展率低于对照组（P〈O．05），完全缓解率高于对照组（P〈O．05）。结论吉西他滨治疗晚期老年非小细胞肺癌效果理想，不良反应少．值得临床推广。

Objective To investigate the efficacy and safety of gemcitabine alone for elderly patients with advanced non-small cell lung cancer.Methods 80 cases of elderly patients with advanced non-small cell lung carcinoma in our hospital from January 2008 to January 2010 were chosen,and then were divided into control group and observation group,40 cases in each group,for patients with medical illness conditioning,the observation group were given geme- itabine alone,the control group were given paelitaxel and cisplatin.Then reactions and statistics of its 2-year locoregion- al control rate,no new distant metastasis and overall survival was compared in the two groups.Results The observation group with leukopenia,thrombocytopenia and gastrointestinal reactions Ⅰ ,Ⅱ, Ⅲ level ratio was less than that of the con- trol group （P〈0.05）; the observation group with 2-year local regional control rate,no new distant metastasis and overall survival was significantly higher than that of the control group （P〈0.05）.The observation group with disease progression rate was lower than that of the control group （P〈0.05）,the complete remission rate was higher than that of the control group （P〈0.05）.Conclusion Gemeitabine for advanced non-small cell lung carcinoma is a satisfactoi~~ method for elder- ly,it has less adverse reactions,so it is worthy of promotion.